Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3342299 | 0.83 | MEN1 (0.39) | CYP2C19SMN1; SMN2EGFR | |
| SCHEMBL17299381 | 0.81 | LTA4H (0.50) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL4558309 | 0.79 | ALDH1A1 (0.41) | NOX1LMNASMN1; SMN2RAB9AMAPT | |
| SCHEMBL4558030 | 0.78 | POLB (0.51) | NOX1SMN1; SMN2NPC1MAOBRAB9A | |
| SCHEMBL4652904 | 0.78 | BACE1 (0.36) | LMNASLC6A2SLC6A3GAA | |
| SCHEMBL15809710 | 0.77 | LMNA (0.56) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL5522119 | 0.76 | LMNA (0.53) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL15809694 | 0.76 | LTA4H (0.55) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL4465723 | 0.75 | ALDH1A1 (0.43) | L3MBTL1 | |
| SCHEMBL7717528 | 0.75 | DUT (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355876-B1 | METHODS OF CHEMICAL SYNTHESIS OF PHENOLIC NITROGEN MUSTARD PRODRUGS | CANCER RES INST ROYAL (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-6916949-B2 | Methods of chemical systhesis of phenolic nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20040087813-A1 | Methods of chemical systhesis of phenolic nitrogen mustard prodrugs | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2004-05-06 | — | — | US | disclosed |
| EP-1355876-A1 | METHODS OF CHEMICAL SYNTHESIS OF PHENOLIC NITROGEN MUSTARD PRODRUGS | Cancer Research Technology Limited (GB) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002060862-A1 | METHODS OF CHEMICAL SYNTHESIS OF PHENOLIC NITROGEN MUSTARD PRODRUGS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087813-A1 | Methods of chemical systhesis of phenolic nitrogen mustard prodrugs | GGH, GLUL, GSS | NOX1 616/4885LMNA 1533/4885CYP1A2 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.